Search

Your search keyword '"Viebig, Nicola K."' showing total 40 results
Start Over Author "Viebig, Nicola K."
40 results on '"Viebig, Nicola K."'

1. Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

Author

Doritchamou, Justin, Nielsen, Morten A., Chêne, Arnaud, Viebig, Nicola K., Lambert, Lynn E., Sander, Adam F., Semblat, Jean-Philippe, Hundt, Sophia, Orr-Gonzalez, Sachy, Janitzek, Christoph Mikkel, Spiegel, Alicia J., Clemmensen, Stine B., Thomas, III, Marvin L., Nason, Martha C., Snow-Smith, Maryonne, Barnafo, Emma K., Shiloach, Joseph, Chen, Beth B., Nadakal, Steven, Highsmith, Kendrick, Ouahes, Tarik, Conteh, Solomon, Sharma, Ankur, Torano, Holly, Butler, Brandi, Reiter, Karine, Rausch, Kelly M., Scaria, Puthupparampil V., Anderson, Charles, Narum, David L., Salanti, Ali, Fried, Michal, Theander, Thor G., Gamain, Benoit, and Duffy, Patrick E.

Published
2023
Full Text
View/download PDF

2. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Author

Sirima, Sodiomon B, Richert, Laura, Chêne, Arnaud, Konate, Amadou T, Campion, Cécilia, Dechavanne, Sébastien, Semblat, Jean-Philippe, Benhamouda, Nadine, Bahuaud, Mathilde, Loulergue, Pierre, Ouédraogo, Alphonse, Nébié, Issa, Kabore, Moïse, Kargougou, Désiré, Barry, Aïssata, Ouattara, San Maurice, Boilet, Valérie, Allais, Florence, Roguet, Gwenaelle, Havelange, Nicolas, Lopez-Perez, Elvira, Kuppers, Alexis, Konaté, Eleine, Roussillon, Caroline, Kanté, Myriam, Belarbi, Linda, Diarra, Amidou, Henry, Noelie, Soulama, Issiaka, Ouédraogo, Amidou, Esperou, Helene, Leroy, Odile, Batteux, Frederic, Tartour, Eric, Viebig, Nicola K, Thiebaut, Rodolphe, Launay, Odile, and Gamain, Benoît

Published
2020
Full Text
View/download PDF

3. Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso

Author

Morter, Richard, primary, Tiono, Alfred B., additional, Nébié, Issa, additional, Hague, Oliver, additional, Ouedraogo, Alphonse, additional, Diarra, Amidou, additional, Viebig, Nicola K., additional, Hill, Adrian V. S., additional, Ewer, Katie J., additional, and Sirima, Sodiomon B., additional

Published
2022
Full Text
View/download PDF

4. A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies

Author

Takashima, Eizo, primary, Nagaoka, Hikaru, additional, Correia, Ricardo, additional, Alves, Paula M., additional, Roldão, António, additional, Christensen, Dennis, additional, Guderian, Jeffrey A., additional, Fukushima, Akihisa, additional, Viebig, Nicola K., additional, Depraetere, Hilde, additional, and Tsuboi, Takafumi, additional

Published
2022
Full Text
View/download PDF

7. Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

Author

Doritchamou, Justin, primary, Nielsen, Morten A., additional, Chêne, Arnaud, additional, Viebig, Nicola K., additional, Lambert, Lynn E., additional, Sander, Adam F., additional, Semblat, Jean-Philippe, additional, Hundt, Sophia, additional, Orr-Gonzalez, Sachy, additional, Janitzek, Christoph M., additional, Spiegel, Alicia J., additional, Clemmensen, Stine B., additional, Thomas, Marvin L., additional, Nason, Martha C., additional, Snow-Smith, Maryonne, additional, Barnafo, Emma K., additional, Shiloach, Joseph, additional, Chen, Beth B., additional, Nadakal, Steven, additional, Highsmith, Kendrick, additional, Ouahes, Tarik, additional, Conteh, Solomon, additional, Sharma, Ankur, additional, Torano, Holly, additional, Butler, Brandi, additional, Reiter, Karine, additional, Rausch, Kelly M., additional, Scaria, Puthupparampil V., additional, Anderson, Charles, additional, Narum, David L., additional, Salanti, Ali, additional, Fried, Michal, additional, Theander, Thor G., additional, Gamain, Benoit, additional, and Duffy, Patrick E., additional

Published
2022
Full Text
View/download PDF

8. Progress and insights toward an effective placental malaria vaccine

Author

Gamain, Benoît, Chêne, Arnaud, Viebig, Nicola K, Tuikue Ndam, Nicaise, Nielsen, Morten A, Gamain, Benoît, Chêne, Arnaud, Viebig, Nicola K, Tuikue Ndam, Nicaise, and Nielsen, Morten A

Abstract

In areas where Plasmodium falciparum transmission is endemic, clinical immunity against malaria is progressively acquired during childhood and adults are usually protected against the severe clinical consequences of the disease. Nevertheless, pregnant women, notably during their first pregnancies, are susceptible to placental malaria and the associated serious clinical outcomes. Placental malaria is characterized by the massive accumulation of P. falciparum infected erythrocytes and monocytes in the placental intervillous spaces leading to maternal anaemia, hypertension, stillbirth and low birth weight due to premature delivery, and foetal growth retardation. Remarkably, the prevalence of placental malaria sharply decreases with successive pregnancies. This protection is associated with the development of antibodies directed towards the surface of P. falciparum-infected erythrocytes from placental origin. Placental sequestration is mediated by the interaction between VAR2CSA, a member of the P. falciparum erythrocyte membrane protein 1 family expressed on the infected erythrocytes surface, and the placental receptor chondroitin sulfate A. VAR2CSA stands today as the leading candidate for a placental malaria vaccine. We recently reported the safety and immunogenicity of two VAR2CSA-derived placental malaria vaccines (PRIMVAC and PAMVAC), spanning the chondroitin sulfate A-binding region of VAR2CSA, in both malaria-naïve and P. falciparum-exposed non-pregnant women in two distinct Phase I clinical trials (ClinicalTrials.gov, NCT02658253 and NCT02647489). This review discusses recent advances in placental malaria vaccine development, with a focus on the recent clinical data, and discusses the next clinical steps to undertake in order to better comprehend vaccine-induced immunity and accelerate vaccine development.

Published
2021

13. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Author

Borrow, Ray, Tiono, Alfred B., Nébié, Issa, Anagnostou, Nicholas, Coulibaly, Aboubacar S., Bowyer, Georgina, Lam, Erika, Bougouma, Edith C., Ouedraogo, Alphonse, Yaro, Jean Baptist B., Barry, Aïssata, Roberts, Rachel, Rampling, Tommy, Bliss, Carly, Hodgson, Susanne, Lawrie, Alison, Ouedraogo, Amidou, Imoukhuede, Egeruan Babatunde, Ewer, Katie J., Viebig, Nicola K., Diarra, Amidou, Leroy, Odile, Bejon, Philip, Hill, Adrian V. S., and Sirima, Sodiomon B.

Subjects
0301 basic medicine, Male, Viral Diseases, Physiology, T-Lymphocytes, Kaplan-Meier Estimate, Biochemistry, law.invention, chemistry.chemical_compound, White Blood Cells, 0302 clinical medicine, Randomized controlled trial, law, Animal Cells, Zoonoses, Immune Physiology, Clinical endpoint, Medicine and Health Sciences, Public and Occupational Health, 030212 general & internal medicine, Enzyme-Linked Immunoassays, Vaccines, Multidisciplinary, Immune System Proteins, Malaria vaccine, T Cells, Immunogenicity, Vaccination and Immunization, 3. Good health, Infectious Diseases, Medicine, Female, Cellular Types, Research Article, Neglected Tropical Diseases, medicine.medical_specialty, Infectious Disease Control, Rabies, Immune Cells, Science, Plasmodium falciparum, Immunology, Enzyme-Linked Immunosorbent Assay, Vaccinia virus, Research and Analysis Methods, complex mixtures, Antibodies, 03 medical and health sciences, Double-Blind Method, Internal medicine, parasitic diseases, Malaria Vaccines, medicine, Parasitic Diseases, Humans, Antigens, Immunoassays, Blood Cells, business.industry, Infant, Biology and Life Sciences, Proteins, Cell Biology, medicine.disease, Tropical Diseases, Kenya, Malaria, Clinical trial, Regimen, 030104 developmental biology, chemistry, Leukocytes, Mononuclear, Immunologic Techniques, Adenoviruses, Simian, Preventive Medicine, Vaccinia, business
Abstract

BackgroundHeterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falciparum infection in United Kingdom adult Phase IIa sporozoite challenge studies (approximately 20-25% sterile protection with similar numbers showing clear delay in time to patency), and greater point efficacy in a trial in Kenyan adults.MethodologyWe conducted the first Phase IIb clinical trial assessing the safety, immunogenicity and efficacy of ChAd63 MVA ME-TRAP in 700 healthy malaria exposed children aged 5-17 months in a highly endemic malaria transmission area of Burkina Faso.ResultsChAd63 MVA ME-TRAP was shown to be safe and immunogenic but induced only moderate T cell responses (median 326 SFU/106 PBMC (95% CI 290-387)) many fold lower than in previous trials. No significant efficacy was observed against clinical malaria during the follow up period, with efficacy against the primary endpoint estimate by proportional analysis being 13.8% (95%CI -42.4 to 47.9) at sixth month post MVA ME-TRAP and 3.1% (95%CI -15.0 to 18.3; p = 0.72) by Cox regression.ConclusionsThis study has confirmed ChAd63 MVA ME-TRAP is a safe and immunogenic vaccine regimen in children and infants with prior exposure to malaria. But no significant protective efficacy was observed in this very highly malaria-endemic setting.Trial registrationClinicalTrials.gov NCT01635647. Pactr.org PACTR201208000404131.

Published
2018

15. OC 8552 EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5–17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO

Author

Tiono, Alfred B, primary, Nebie, Issa, additional, Anagnostou, Nicholas, additional, Coulibaly, Sam A, additional, Lawrie, Alison, additional, Bougouma, Edith C, additional, Ouedraogo, Alphonse, additional, Yaro, Jean Baptist, additional, Barry, Aïssata, additional, Roberts, Rachel, additional, Ouedraogo, Amidou, additional, Ewer, Katie J, additional, Viebig, Nicola K, additional, Diarra, Amidou, additional, Leroy, Odile, additional, Bejon, Philip, additional, Hill, Adrian, additional, and Sirima, Sodiomon B, additional

Published
2019
Full Text
View/download PDF

17. OC 8582 A PHASE IA/B STUDY TO ASSESS SAFETY AND IMMUNOGENICITY OF PLACENTAL MALARIA VACCINE CANDIDATE: PRELIMINARY RESULTS OF THE PRIMALVAC TRIAL

Author

Konate, Amadou, primary, Richert, Laura, additional, Chêne, Arnaud, additional, Semblat, Jean-Philippe, additional, Roguet, Gwenaelle, additional, Benhamouda, Nadine, additional, Bahuaud, Mathilde, additional, Havelange, Nicolas, additional, Kuppers, Alexis, additional, Campion, Cécilia, additional, Boilet, Valérie, additional, Gueguen, Sonia, additional, Loulergue, Pierre, additional, Leroy, Odile, additional, Batteux, Frederic, additional, Tartour, Eric, additional, Viebig, Nicola K, additional, Thiebaut, Rodolphe, additional, Sirima, Sodiomon B, additional, Launay, Odile, additional, and Gamain, Benoit, additional

Published
2019
Full Text
View/download PDF

18. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Author

Tiono, Alfred B., primary, Nébié, Issa, additional, Anagnostou, Nicholas, additional, Coulibaly, Aboubacar S., additional, Bowyer, Georgina, additional, Lam, Erika, additional, Bougouma, Edith C., additional, Ouedraogo, Alphonse, additional, Yaro, Jean Baptist B., additional, Barry, Aïssata, additional, Roberts, Rachel, additional, Rampling, Tommy, additional, Bliss, Carly, additional, Hodgson, Susanne, additional, Lawrie, Alison, additional, Ouedraogo, Amidou, additional, Imoukhuede, Egeruan Babatunde, additional, Ewer, Katie J., additional, Viebig, Nicola K., additional, Diarra, Amidou, additional, Leroy, Odile, additional, Bejon, Philip, additional, Hill, Adrian V. S., additional, and Sirima, Sodiomon B., additional

Published
2018
Full Text
View/download PDF

19. Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites

Author

Scherf Artur, Gysin Jürg, Lépolard Catherine, Dechavanne Sébastien, Viebig Nicola K, Fernandez Pablo, and Gamain Benoit

Subjects
Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Pregnancy-associated malaria (PAM) is a serious consequence of Plasmodium falciparum-infected erythrocytes sequestration in the placenta through the adhesion to the placental receptor chondroitin sulfate A (CSA). Although women become resistant to PAM as they acquire transcending inhibitory immunity against CSA-binding parasites, hundreds of thousands of lives could be saved if a prophylactic vaccine targeting the surface proteins of placental parasites could be designed. Recent works point to the variant protein var2CSA as the key target for the development of a pregnancy-associated malaria vaccine. However, designing such a prophylactic vaccine has been hindered by the difficulty in identifying regions of var2CSA that could elicit broadly neutralizing and adhesion-blocking antibodies. Methods Var2CSA is a very large protein with an estimated molecular weight of 350 kDa, and can be divided into six cysteine rich Duffy binding-like domains (DBL). The human embryonic kidney 293 cell line (HEK293) was used to produce secreted soluble recombinant forms of var2CSA DBL domains. The Escherichia coli expression system was also assessed for the domains not expressed or expressed in low amount in the HEK293 system. To investigate whether var2CSA binding DBL domains can induce biologically active antibodies recognizing the native var2CSA and blocking the interaction, mice were immunized with the refolded DBL3-X or the HEK293 secreted DBL6-ε domains. Results Using the HEK293 expression system, DBL1-X, DBL4-ε and DBL6-ε were produced at relatively high levels in the culture supernatant, while DBL3-X and DBL5-ε were produced at much lower levels. DBL2-X and DBL3-X domains were obtained after refolding of the inclusion bodies produced in E. coli. Importantly, mice antisera raised against the recombinant DBL6-ε domain, specifically reacted against the surface of CSA-binding parasites and revealed adhesion blocking activity. Conclusion This is the first report showing inhibitory binding antibodies obtained through a var2CSA recombinant DBL domain immunization protocol. These results support the current strategies using var2CSA as immunogen in the aim of blocking placental sequestration of malaria parasites. This work is a step towards the development of a var2CSA based vaccine that will prevent pregnancy-associated malaria and improve pregnancy outcomes.

Published
2008
Full Text
View/download PDF

20. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

Author

Ogwang, Caroline, Kimani, Domtila, Edwards, Nick J., Roberts, Rachel, Mwacharo, Jedidah, Bowyer, Georgina, Bliss, Carly, Hodgson, Susanne H., Njuguna, Patricia, Viebig, Nicola K., Nicosia, Alfredo, Gitau, Evelyn, Douglas, Sandy, Illingworth, Joe, Marsh, Kevin, Lawrie, Alison, Imoukhuede, Egeruan B., Ewer, Katie, Urban, Britta C., Hill, Adrian V. S., Bejon, Philip, Leroy, Odile, Cisse, Badara, Sirima, Sodiomon, Bojang, Kalifa, Murphy, Georgina, Karanja, Henry, Nyamako, Lydiah, De Cassan, Simone, Awuondo, Ken, Kwiatkowski, Dominic, Rockett, Kirk, Gilbert, Sarah, Anagnostou, Nicholas, Soipei, Peninah, Peshu, Judy, Petersen, Ines, Mutinda, Brian, Waithira, Naomi, Bashraheil, Mahfudh, Shangala, Jimmy, Moyle, Sarah, Berrie, Eleanor, Targett, Geoffrey, Thera, Mahamadou, Milligan, Paul, Ogutu, Bernhards, Ogwang, Caroline, Kimani, Domtila, Edwards, Nick J., Roberts, Rachel, Mwacharo, Jedidah, Bowyer, Georgina, Bliss, Carly, Hodgson, Susanne H., Njuguna, Patricia, Viebig, Nicola K., Nicosia, Alfredo, Gitau, Evelyn, Douglas, Sandy, Illingworth, Joe, Marsh, Kevin, Lawrie, Alison, Imoukhuede, Egeruan B., Ewer, Katie, Urban, Britta C., Hill, Adrian V. S., Bejon, Philip, Leroy, Odile, Cisse, Badara, Sirima, Sodiomon, Bojang, Kalifa, Murphy, Georgina, Karanja, Henry, Nyamako, Lydiah, De Cassan, Simone, Awuondo, Ken, Kwiatkowski, Dominic, Rockett, Kirk, Gilbert, Sarah, Anagnostou, Nichola, Soipei, Peninah, Peshu, Judy, Petersen, Ine, Mutinda, Brian, Waithira, Naomi, Bashraheil, Mahfudh, Shangala, Jimmy, Moyle, Sarah, Berrie, Eleanor, Targett, Geoffrey, Thera, Mahamadou, Milligan, Paul, and Ogutu, Bernhards

Subjects
Adult, Male, Modified vaccinia Ankara, Cellular immunity, Pan troglodytes, Genotype, Plasmodium falciparum, Protozoan Proteins, Vaccinia virus, Kaplan-Meier Estimate, Parasitemia, Biology, Polymerase Chain Reaction, Article, Viral vector, Epitopes, Young Adult, Rabies vaccine, Malaria Vaccine, Malaria Vaccines, parasitic diseases, medicine, Animals, Humans, Malaria, Falciparum, Immunization Schedule, Proportional Hazards Models, Animal, Medicine (all), Pan troglodyte, Protozoan Protein, General Medicine, medicine.disease, biology.organism_classification, Kenya, Virology, Vaccinia viru, 3. Good health, Algorithm, Vaccination, Immunology, Proportional Hazards Model, Adenoviruses, Simian, Epitope, Algorithms, Malaria, Human, medicine.drug
Abstract

Protective immunity to the liver stage of the malaria parasite can be conferred by vaccine-induced T cells, but no subunit vaccination approach based on cellular immunity has shown efficacy in field studies. We randomly allocated 121 healthy adult male volunteers in Kilifi, Kenya, to vaccination with the recombinant viral vectors chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA), both encoding the malaria peptide sequence ME-TRAP (the multiple epitope string and thrombospondin-related adhesion protein), or to vaccination with rabies vaccine as a control. We gave antimalarials to clear parasitemia and conducted PCR (polymerase chain reaction) analysis on blood samples three times a week to identify infection with the malaria parasite Plasmodium falciparum. On Cox regression, vaccination reduced the risk of infection by 67% [95% confidence interval (CI), 33 to 83%; P = 0.002] during 8 weeks of monitoring. T cell responses to TRAP peptides 21 to 30 were significantly associated with protection (hazard ratio, 0.24; 95% CI, 0.08 to 0.75; P = 0.016).

Published
2015

21. Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

Author

Mensah, Victorine A., primary, Roetynck, Sophie, additional, Kanteh, Ebrima K., additional, Bowyer, Georgina, additional, Ndaw, Amy, additional, Oko, Francis, additional, Bliss, Carly M., additional, Jagne, Ya Jankey, additional, Cortese, Riccardo, additional, Nicosia, Alfredo, additional, Roberts, Rachel, additional, D’Alessio, Flavia, additional, Leroy, Odile, additional, Faye, Babacar, additional, Kampmann, Beate, additional, Cisse, Badara, additional, Bojang, Kalifa, additional, Gerry, Stephen, additional, Viebig, Nicola K., additional, Lawrie, Alison M., additional, Clarke, Ed, additional, Imoukhuede, Egeruan B., additional, Ewer, Katie J., additional, Hill, Adrian V. S., additional, and Afolabi, Muhammed O., additional

Published
2017
Full Text
View/download PDF

22. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

Author

Payne, Ruth O., primary, Silk, Sarah E., additional, Elias, Sean C., additional, Miura, Kazutoyo, additional, Diouf, Ababacar, additional, Galaway, Francis, additional, de Graaf, Hans, additional, Brendish, Nathan J., additional, Poulton, Ian D., additional, Griffiths, Oliver J., additional, Edwards, Nick J., additional, Jin, Jing, additional, Labbé, Geneviève M., additional, Alanine, Daniel G.W., additional, Siani, Loredana, additional, Di Marco, Stefania, additional, Roberts, Rachel, additional, Green, Nicky, additional, Berrie, Eleanor, additional, Ishizuka, Andrew S., additional, Nielsen, Carolyn M., additional, Bardelli, Martino, additional, Partey, Frederica D., additional, Ofori, Michael F., additional, Barfod, Lea, additional, Wambua, Juliana, additional, Murungi, Linda M., additional, Osier, Faith H., additional, Biswas, Sumi, additional, McCarthy, James S., additional, Minassian, Angela M., additional, Ashfield, Rebecca, additional, Viebig, Nicola K., additional, Nugent, Fay L., additional, Douglas, Alexander D., additional, Vekemans, Johan, additional, Wright, Gavin J., additional, Faust, Saul N., additional, Hill, Adrian V.S., additional, Long, Carole A., additional, Lawrie, Alison M., additional, and Draper, Simon J., additional

Published
2017
Full Text
View/download PDF

23. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

Author

Payne, Ruth O, Silk, Sarah E, Elias, Sean C, Miura, Kazutoyo, Diouf, Ababacar, Galaway, Francis, de Graaf, Hans, Brendish, Nathan J, Poulton, Ian D, Griffiths, Oliver J, Edwards, Nick J, Jin, Jing, Labbé, Geneviève M, Alanine, Daniel Gw, Siani, Loredana, Di Marco, Stefania, Roberts, Rachel, Green, Nicky, Berrie, Eleanor, Ishizuka, Andrew S, Nielsen, Carolyn M, Bardelli, Martino, Partey, Frederica D, Ofori, Michael F, Barfod, Lea, Wambua, Juliana, Murungi, Linda M, Osier, Faith H, Biswas, Sumi, McCarthy, James S, Minassian, Angela M, Ashfield, Rebecca, Viebig, Nicola K, Nugent, Fay L, Douglas, Alexander D, Vekemans, Johan, Wright, Gavin J, Faust, Saul N, Hill, Adrian Vs, Long, Carole A, Lawrie, Alison M, Draper, Simon J, Payne, Ruth O, Silk, Sarah E, Elias, Sean C, Miura, Kazutoyo, Diouf, Ababacar, Galaway, Francis, de Graaf, Hans, Brendish, Nathan J, Poulton, Ian D, Griffiths, Oliver J, Edwards, Nick J, Jin, Jing, Labbé, Geneviève M, Alanine, Daniel Gw, Siani, Loredana, Di Marco, Stefania, Roberts, Rachel, Green, Nicky, Berrie, Eleanor, Ishizuka, Andrew S, Nielsen, Carolyn M, Bardelli, Martino, Partey, Frederica D, Ofori, Michael F, Barfod, Lea, Wambua, Juliana, Murungi, Linda M, Osier, Faith H, Biswas, Sumi, McCarthy, James S, Minassian, Angela M, Ashfield, Rebecca, Viebig, Nicola K, Nugent, Fay L, Douglas, Alexander D, Vekemans, Johan, Wright, Gavin J, Faust, Saul N, Hill, Adrian Vs, Long, Carole A, Lawrie, Alison M, and Draper, Simon J

Abstract

The development of a highly effective vaccine remains a key strategic goal to aid the control and eventual eradication of Plasmodium falciparum malaria. In recent years, the reticulocyte-binding protein homolog 5 (RH5) has emerged as the most promising blood-stage P. falciparum candidate antigen to date, capable of conferring protection against stringent challenge in Aotus monkeys. We report on the first clinical trial to our knowledge to assess the RH5 antigen - a dose-escalation phase Ia study in 24 healthy, malaria-naive adult volunteers. We utilized established viral vectors, the replication-deficient chimpanzee adenovirus serotype 63 (ChAd63), and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA), encoding RH5 from the 3D7 clone of P. falciparum. Vaccines were administered i.m. in a heterologous prime-boost regimen using an 8-week interval and were well tolerated. Vaccine-induced anti-RH5 serum antibodies exhibited cross-strain functional growth inhibition activity (GIA) in vitro, targeted linear and conformational epitopes within RH5, and inhibited key interactions within the RH5 invasion complex. This is the first time to our knowledge that substantial RH5-specific responses have been induced by immunization in humans, with levels greatly exceeding the serum antibody responses observed in African adults following years of natural malaria exposure. These data support the progression of RH5-based vaccines to human efficacy testing.

Published
2017

24. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

Author

Bliss, Carly M., primary, Drammeh, Abdoulie, additional, Bowyer, Georgina, additional, Sanou, Guillaume S., additional, Jagne, Ya Jankey, additional, Ouedraogo, Oumarou, additional, Edwards, Nick J., additional, Tarama, Casimir, additional, Ouedraogo, Nicolas, additional, Ouedraogo, Mireille, additional, Njie-Jobe, Jainaba, additional, Diarra, Amidou, additional, Afolabi, Muhammed O., additional, Tiono, Alfred B., additional, Yaro, Jean Baptiste, additional, Adetifa, Uche J., additional, Hodgson, Susanne H., additional, Anagnostou, Nicholas A., additional, Roberts, Rachel, additional, Duncan, Christopher J.A., additional, Cortese, Riccardo, additional, Viebig, Nicola K., additional, Leroy, Odile, additional, Lawrie, Alison M., additional, Flanagan, Katie L., additional, Kampmann, Beate, additional, Imoukhuede, Egeruan B., additional, Sirima, Sodiomon B., additional, Bojang, Kalifa, additional, Hill, Adrian V.S., additional, Nébié, Issa, additional, and Ewer, Katie J., additional

Published
2017
Full Text
View/download PDF

25. Clinical development of placental malaria vaccines and immunoassays harmonization:a workshop report

Author

Chêne, Arnaud, Houard, Sophie, Nielsen, Morten A, Hundt, Sophia, D'Alessio, Flavia, Sirima, Sodiomon B, Luty, Adrian J F, Duffy, Patrick, Leroy, Odile, Gamain, Benoit, Viebig, Nicola K, Chêne, Arnaud, Houard, Sophie, Nielsen, Morten A, Hundt, Sophia, D'Alessio, Flavia, Sirima, Sodiomon B, Luty, Adrian J F, Duffy, Patrick, Leroy, Odile, Gamain, Benoit, and Viebig, Nicola K

Abstract

Placental malaria caused by Plasmodium falciparum infection constitutes a major health problem manifesting as severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. Prevention of placental malaria currently relies on two key strategies that are losing efficacy due to spread of resistance: long-lasting insecticide-treated nets and intermittent preventive treatment during pregnancy. A placental malaria vaccine would be an attractive, cost-effective complement to the existing control tools. Two placental malaria vaccine candidates are currently in Phase Ia/b clinical trials. During two workshops hosted by the European Vaccine Initiative, one in Paris in April 2014 and the other in Brussels in November 2014, the main actors in placental malaria vaccine research discussed the harmonization of clinical development plans and of the immunoassays with a goal to define standards that will allow comparative assessment of different placental malaria vaccine candidates. The recommendations of these workshops should guide researchers and clinicians in the further development of placental malaria vaccines.

Published
2016

27. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

Author

Afolabi, Muhammed O, primary, Tiono, Alfred B, additional, Adetifa, Uche J, additional, Yaro, Jean Baptiste, additional, Drammeh, Abdoulie, additional, Nébié, Issa, additional, Bliss, Carly, additional, Hodgson, Susanne H, additional, Anagnostou, Nicholas A, additional, Sanou, Guillaume S, additional, Jagne, Ya Jankey, additional, Ouedraogo, Oumarou, additional, Tamara, Casimir, additional, Ouedraogo, Nicolas, additional, Ouedraogo, Mirielle, additional, Njie-Jobe, Jainaba, additional, Diarra, Amidou, additional, Duncan, Christopher JA, additional, Cortese, Riccardo, additional, Nicosia, Alfredo, additional, Roberts, Rachel, additional, Viebig, Nicola K, additional, Leroy, Odile, additional, Lawrie, Alison M, additional, Flanagan, Katie L, additional, Kampman, Beate, additional, Bejon, Philip, additional, Imoukhuede, Egeruan B, additional, Ewer, Katie J, additional, Hill, Adrian VS, additional, Bojang, Kalifa, additional, and Sirima, Sodiomon B, additional

Published
2016
Full Text
View/download PDF

28. Workshop report: Malaria vaccine development in Europe–preparing for the future

Author

Viebig, Nicola K., primary, D’Alessio, Flavia, additional, Draper, Simon J., additional, Sim, B. Kim Lee, additional, Mordmüller, Benjamin, additional, Bowyer, Paul W., additional, Luty, Adrian J.F., additional, Jungbluth, Stefan, additional, Chitnis, Chetan E., additional, Hill, Adrian V.S., additional, Kremsner, Peter, additional, Craig, Alister G., additional, Kocken, Clemens H.M., additional, and Leroy, Odile, additional

Published
2015
Full Text
View/download PDF

29. Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations

Author

Kimani, Domtila, primary, Jagne, Ya Jankey, additional, Cox, Momodou, additional, Kimani, Eva, additional, Bliss, Carly M, additional, Gitau, Evelyn, additional, Ogwang, Caroline, additional, Afolabi, Muhammed O, additional, Bowyer, Georgina, additional, Collins, Katharine A, additional, Edwards, Nick, additional, Hodgson, Susanne H, additional, Duncan, Christopher J A, additional, Spencer, Alexandra J, additional, Knight, Miguel G, additional, Drammeh, Abdoulie, additional, Anagnostou, Nicholas A, additional, Berrie, Eleanor, additional, Moyle, Sarah, additional, Gilbert, Sarah C, additional, Soipei, Peninah, additional, Okebe, Joseph, additional, Colloca, Stefano, additional, Cortese, Riccardo, additional, Viebig, Nicola K, additional, Roberts, Rachel, additional, Lawrie, Alison M, additional, Nicosia, Alfredo, additional, Imoukhuede, Egeruan B, additional, Bejon, Philip, additional, Chilengi, Roma, additional, Bojang, Kalifa, additional, Flanagan, Katie L, additional, Hill, Adrian V S, additional, Urban, Britta C, additional, and Ewer, Katie J, additional

Published
2014
Full Text
View/download PDF

30. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Author

Mensah, Victorine A., Gueye, Aly, Ndiaye, Magatte, Edwards, Nick J., Wright, Danny, Anagnostou, Nicholas A., Syll, Massamba, Ndaw, Amy, Abiola, Annie, Bliss, Carly, Gomis, Jules-François, Petersen, Ines, Ogwang, Caroline, Dieye, Tandakha, Viebig, Nicola K., Lawrie, Alison M., Roberts, Rachel, Nicosia, Alfredo, Faye, Babacar, and Gaye, Oumar

Subjects
MALARIA treatment, MALARIA transmission, PLASMODIUM falciparum, VACCINE effectiveness, POLYMERASE chain reaction, DISEASES in adults
Abstract

Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver viral vectors encoding the pre-erythrocytic antigen ME-TRAP (multiple epitope thrombospondin-related adhesion protein) have shown promising safety, immunogenicity and efficacy in sporozoite challenge studies. More recently, a study in Kenyan adults, similar to that reported here, showed substantial efficacy against P. falciparum infection. One hundred and twenty healthy male volunteers, living in a malaria endemic area of Senegal were randomised to receive either the Chimpanzee adenovirus (ChAd63) ME-TRAP as prime vaccination, followed eight weeks later by modified vaccinia Ankara (MVA) also encoding ME-TRAP as booster, or two doses of anti-rabies vaccine as a comparator. Prior to follow-up, antimalarials were administered to clear parasitaemia and then participants were monitored by PCR for malaria infection for eight weeks. The primary endpoint was time-to-infection with P. falciparum malaria, determined by two consecutive positive PCR results. Secondary endpoints included adverse event reporting, measures of cellular and humoral immunogenicity and a meta-analysis of combined vaccine efficacy with the parallel study in Kenyan adults.We show that this pre-erythrocytic malaria vaccine is safe and induces significant immunogenicity, with a peak T-cell response at seven days after boosting of 932 Spot Forming Cells (SFC)/106 Peripheral Blood Mononuclear Cells(PBMC) compared to 57 SFC/ 106 PBMCs in the control group. However, a vaccine efficacy was not observed: 12 of 57 ME-TRAP vaccinees became PCR positive during the intensive monitoring period as compared to 13 of the 58 controls (P = 0.80). This trial confirms that vaccine efficacy against malaria infection in adults may be rapidly assessed using this efficient and cost-effective clinical trial design. Further efficacy evaluation of this vectored candidate vaccine approach in other malaria transmission settings and age-de-escalation into the main target age groups for a malaria vaccine is in progress. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

32. Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

Author

Ogwang, Caroline, primary, Afolabi, Muhammed, additional, Kimani, Domtila, additional, Jagne, Ya Jankey, additional, Sheehy, Susanne H., additional, Bliss, Carly M., additional, Duncan, Christopher J. A., additional, Collins, Katharine A., additional, Garcia Knight, Miguel A., additional, Kimani, Eva, additional, Anagnostou, Nicholas A., additional, Berrie, Eleanor, additional, Moyle, Sarah, additional, Gilbert, Sarah C., additional, Spencer, Alexandra J., additional, Soipei, Peninah, additional, Mueller, Jenny, additional, Okebe, Joseph, additional, Colloca, Stefano, additional, Cortese, Riccardo, additional, Viebig, Nicola K., additional, Roberts, Rachel, additional, Gantlett, Katherine, additional, Lawrie, Alison M., additional, Nicosia, Alfredo, additional, Imoukhuede, Egeruan B., additional, Bejon, Philip, additional, Urban, Britta C., additional, Flanagan, Katie L., additional, Ewer, Katie J., additional, Chilengi, Roma, additional, Hill, Adrian V. S., additional, and Bojang, Kalifa, additional

Published
2013
Full Text
View/download PDF

35. Dissection of the Role of PfEMP1 and ICAM-1 in the Sensing of Plasmodium falciparum-Infected Erythrocytes by Natural Killer Cells

Author

Baratin, Myriam, primary, Roetynck, Sophie, additional, Pouvelle, Bruno, additional, Lemmers, Céline, additional, Viebig, Nicola K., additional, Johansson, Sofia, additional, Bierling, Philippe, additional, Scherf, Artur, additional, Gysin, Jürg, additional, Vivier, Eric, additional, and Ugolini, Sophie, additional

Published
2007
Full Text
View/download PDF

39. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparuminfection in Kenyan adults

Author

Ogwang, Caroline, Kimani, Domtila, Edwards, Nick J., Roberts, Rachel, Mwacharo, Jedidah, Bowyer, Georgina, Bliss, Carly, Hodgson, Susanne H., Njuguna, Patricia, Viebig, Nicola K., Nicosia, Alfredo, Gitau, Evelyn, Douglas, Sandy, Illingworth, Joe, Marsh, Kevin, Lawrie, Alison, Imoukhuede, Egeruan B., Ewer, Katie, Urban, Britta C., S. Hill, Adrian V., Bejon, Philip, Leroy, Odile, Cisse, Badara, Sirima, Sodiomon, Bojang, Kalifa, Murphy, Georgina, Karanja, Henry, Nyamako, Lydiah, De Cassan, Simone, Awuondo, Ken, Kwiatkowski, Dominic, Rockett, Kirk, Gilbert, Sarah, Anagnostou, Nicholas, Soipei, Peninah, Peshu, Judy, Petersen, Ines, Mutinda, Brian, Waithira, Naomi, Bashraheil, Mahfudh, Shangala, Jimmy, Moyle, Sarah, Berrie, Eleanor, Targett, Geoffrey, Thera, Mahamadou, Milligan, Paul, Ogutu, Bernhards, and Etyang, Anthony

Abstract

Vaccination with the recombinant viral vectors chimpanzee adenovirus 63 followed by modified vaccinia Ankara both encoding the malaria sequence ME-TRAP conferred 67% protection against infection with Plasmodium falciparumin Kenyan adults.

Published
2015
Full Text
View/download PDF

40. Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

Author

Victorine A. Mensah, Sophie Roetynck, Ebrima K. Kanteh, Georgina Bowyer, Amy Ndaw, Francis Oko, Carly M. Bliss, Ya Jankey Jagne, Riccardo Cortese, Alfredo Nicosia, Rachel Roberts, Flavia D’Alessio, Odile Leroy, Babacar Faye, Beate Kampmann, Badara Cisse, Kalifa Bojang, Stephen Gerry, Nicola K. Viebig, Alison M. Lawrie, Ed Clarke, Egeruan B. Imoukhuede, Katie J. Ewer, Adrian V. S. Hill, Muhammed O. Afolabi, Mensah, Victorine A., Roetynck, Sophie, Kanteh, Ebrima K., Bowyer, Georgina, Ndaw, Amy, Oko, Franci, Bliss, Carly M., Jagne, Ya Jankey, Cortese, Riccardo, Nicosia, Alfredo, Roberts, Rachel, D'Alessio, Flavia, Leroy, Odile, Faye, Babacar, Kampmann, Beate, Cisse, Badara, Bojang, Kalifa, Gerry, Stephen, Viebig, Nicola K., Lawrie, Alison M., Clarke, Ed, Imoukhuede, Egeruan B., Ewer, Katie J., Hill, Adrian V. S., and Afolabi, Muhammed O.

Subjects
lcsh:Immunologic diseases. Allergy, 0301 basic medicine, Cellular immunity, 030231 tropical medicine, Immunology, malaria, PROTEIN, complex mixtures, CHAD63, law.invention, 03 medical and health sciences, chemistry.chemical_compound, GUERIN VACCINATION, 0302 clinical medicine, Randomized controlled trial, law, INFECTION, medicine, Immunology and Allergy, Cytokine, cellular immune response, MVA ME-TRAP, clinical trials, Science & Technology, NEWBORNS, business.industry, Immunogenicity, T-CELL RESPONSE, vaccines, medicine.disease, Clinical Trial, cytokines, 3. Good health, Clinical trial, Vaccination, 030104 developmental biology, ANTIBODY, Immunization, chemistry, WEST-AFRICAN CHILDREN, Vaccinia, lcsh:RC581-607, business, Vaccine, Life Sciences & Biomedicine, IFN-GAMMA PRODUCTION, Malaria
Abstract

BACKGROUND: Heterologous prime-boost vaccination with chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) encoding multiple epitope string thrombospondin-related adhesion protein (ME-TRAP) has shown acceptable safety and promising immunogenicity in African adult and pediatric populations. If licensed, this vaccine could be given to infants receiving routine childhood immunizations. We therefore evaluated responses to ChAd63 MVA ME-TRAP when co-administered with routine Expanded Program on Immunization (EPI) vaccines. METHODS: We enrolled 65 Gambian infants and neonates, aged 16, 8, or 1 week at first vaccination and randomized them to receive either ME-TRAP and EPI vaccines or EPI vaccines only. Safety was assessed by the description of vaccine-related adverse events (AEs). Immunogenicity was evaluated using IFNγ enzyme-linked immunospot, whole-blood flow cytometry, and anti-TRAP IgG ELISA. Serology was performed to confirm all infants achieved protective titers to EPI vaccines. RESULTS: The vaccines were well tolerated in all age groups with no vaccine-related serious AEs. High-level TRAP-specific IgG and T cell responses were generated after boosting with MVA. CD8+ T cell responses, previously found to correlate with protection, were induced in all groups. Antibody responses to EPI vaccines were not altered significantly. CONCLUSION: Malaria vectored prime-boost vaccines co-administered with routine childhood immunizations were well tolerated. Potent humoral and cellular immunity induced by ChAd63 MVA ME-TRAP did not reduce the immunogenicity of co-administered EPI vaccines, supporting further evaluation of this regimen in infant populations. CLINICAL TRIAL REGISTRATION: The clinical trial was registered on http://Clinicaltrials.gov (NCT02083887) and the Pan-African Clinical Trials Registry (PACTR201402000749217).

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results